HC Wainwright Reaffirms Neutral Rating for Ventyx Biosciences (NASDAQ:VTYX)

HC Wainwright reiterated their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports.

Separately, Oppenheimer reaffirmed an "outperform" rating and issued a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Ventyx Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.

Ventyx Biosciences Price Performance

NASDAQ VTYX traded down $0.01 on Tuesday, hitting $1.94. The company had a trading volume of 1,170,484 shares, compared to its average volume of 2,210,835. The company's fifty day moving average price is $2.29 and its 200-day moving average price is $2.28. The company has a market capitalization of $137.18 million, a PE ratio of -0.82 and a beta of 0.55. Ventyx Biosciences has a 12-month low of $1.67 and a 12-month high of $11.48.

Insider Activity at Ventyx Biosciences

In related news, Director Sheila Gujrathi acquired 130,000 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average cost of $2.31 per share, for a total transaction of $300,300.00. Following the acquisition, the director now owns 130,000 shares in the company, valued at approximately $300,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider John Nuss sold 13,161 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $2.26, for a total transaction of $29,743.86. Following the transaction, the insider now directly owns 485,701 shares of the company's stock, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders bought 630,000 shares of company stock valued at $1,262,415. 18.18% of the stock is owned by company insiders.

Hedge Funds Weigh In On Ventyx Biosciences

Large investors have recently made changes to their positions in the stock. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences in the 3rd quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock valued at $30,000 after buying an additional 5,310 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Ventyx Biosciences in the 3rd quarter valued at $42,000. The Manufacturers Life Insurance Company lifted its stake in Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock worth $56,000 after acquiring an additional 7,096 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Ventyx Biosciences during the 2nd quarter valued at about $58,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.